Form 4: Amphastar Director Gayle Deflin Receives Equity Grant

Director Gayle Deflin acquired 8,143 restricted stock units and 17,365 stock options as part of an annual equity grant.

Summary

• Director Gayle Deflin was granted 8,143 restricted stock units (RSUs) on June 1, 2026.
• Director Gayle Deflin was granted 17,365 stock options with an exercise price of $18.42 on June 1, 2026.
• Both the RSUs and the stock options are scheduled to vest in full on June 1, 2027.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 19,057 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule ensures retention of board leadership for at least one year.

Negatives

• The issuance of new equity grants results in minor dilution to existing shareholders.

Risks

• Potential for future dilution if additional equity-based compensation is issued to board members or executives.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the pharmaceutical industry to ensure director alignment with long-term performance goals.

Comparison to Industry Standards

• The use of RSUs and stock options as a component of director compensation is consistent with standard practices for mid-cap pharmaceutical companies.
• Vesting periods of one year for director equity are common among peers in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on June 1, 2027.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Equity Compensation, Director Compensation